CV earnings analysis
What we found in CV's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
CapsoVision delivered 10% year-over-year Q2 revenue growth to $3.643 million and reported a 13% increase in capsule volumes, but profitability deteriorated as operating expenses rose 46% and the operating loss expanded to $7.580 million. Gross margin declined to 51% from 55%, while six-month operating cash use reached $14.469 million and management disclosed substantial doubt about the company's ability to continue as a going concern. Clinical and product milestones remain constructive, including completion of enrollment for the 801-patient CapsoCam Colon study and anticipated Q3 2026 AI clearance, but additional financing appears necessary and the new $100 million ATM creates significant dilution risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue and Capsule Volumes Grew
- Q2 revenue increased 10% year over year to $3.643 million from $3.315 million, driven primarily by a 13% increase in CapsoCam Plus capsules sold. International revenue increased 20% and represented 25% of total revenue versus 23% in the prior-year quarter.
- Gross Profit Increased Despite Margin Pressure
- Gross profit increased 3% to $1.871 million from $1.811 million, although gross margin declined to 51% from 55%. Management attributed the margin pressure to approximately 3% lower average selling prices, competitive pricing, and customs and tariff costs.
- Colon Study Enrollment Completed
- The second arm of the CapsoCam Colon pivotal study completed enrollment with 801 patients enrolled at up to 20 sites. Management expects to submit the related 510(k) application for the second-generation product in Q4 2026.
- AI Commercialization Progressed
- Management expects FDA clearance for the CapsoCam Plus AI feature by the end of Q3 2026 after submitting additional demographic analysis by the end of August 2026. The company had also commercialized the product in the EU by the filing date.
- New $100 Million ATM Facility
- The company entered an at-the-market offering agreement on August 13, 2026 permitting sales of up to $100 million of common stock. Although there is no obligation to sell shares, the facility provides a potential source of liquidity.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-Concern and Funding Risk
- The filing states that substantial doubt exists about the company's ability to continue as a going concern within one year. At June 30, 2026, cash was $9.077 million, while six-month operating cash usage was $14.469 million and management said existing cash would not fund operations for at least the next 12 months.
- Losses and R&D Spending Accelerated
- Operating expenses increased 46% year over year to $9.451 million, including a 57% increase in R&D expense to $5.309 million. The quarterly operating loss widened 63% to $7.580 million from $4.651 million, and the six-month accumulated deficit reached $170.2 million.
- Cash Burn and Inventory Build
- Cash and cash equivalents declined to $9.077 million from $10.112 million at December 31, 2025 despite $13.509 million of financing cash inflows. The company also reported a $1.717 million inventory cash outflow and $1.0 million of raw-material purchase commitments.
- Potential Equity Dilution
- The new ATM program permits issuance of up to $100 million of common stock, creating a material potential dilution risk. Shares outstanding increased to 50.032 million at June 30, 2026 from 46.865 million at December 31, 2025 after the private placement and other equity issuances.
- Regulatory and Clinical Timing Risk
- The company continues to face regulatory execution risk: the CapsoCam Colon 510(k) is planned for Q4 2026, while the CapsoCam Plus AI clearance is anticipated by the end of Q3 2026. The pancreatic-cancer UGI study had enrolled only 3 of up to 140 patients, and the company expects to resubmit its Breakthrough Device application after the study.
- Tariff and Asian Supply Exposure
- The filing highlights intensified tariff and supply-chain exposure. Six-month costs of revenue increased 16% to $3.235 million, including approximately $0.1 million of increased customs and tariff costs, while the company relies substantially on suppliers and contract manufacturers in Asia and had $2.3 million payable to Canon at June 30, 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.15
- Gross margin
- 51%
- Segment
- Capsule Endoscopy Segment: $3.643 million of revenue in Q2 2026 versus $3.315 million in Q2 2025; the Company has one operating and reportable segment.
- Segment
- U.S. products: $2.526 million versus $2.353 million; U.S. services: $0.200 million versus $0.200 million; international products: $0.917 million versus $0.762 million.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects to submit the second-generation CapsoCam Colon 510(k) application in Q4 2026, expects FDA clearance for CapsoCam Plus AI by the end of Q3 2026 with U.S. commercialization shortly thereafter, and expects full commercialization of the capsule delivery device in Q4 2026.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- CapsoVision's Q1 2026 results show revenue of $2.79 million, marginally up from $2.78 million in the prior year, while gross margin decreased to 48% from 54% due to rising costs. Despite an EPS of -$0.15, slightly…
- 10-K · March 26, 2026
- CapsoVision reports continued commercial growth in its CapsoCam Plus franchise with CapsoCam Plus revenue of approximately $13.6 million in 2025 (up ~15% from $11.8 million in 2024) and >161,000 patients having used the…
- 10-Q · November 13, 2025
- CapsoVision reported Q3 2025 revenue of $3,538,000, up 19.3% year-over-year and ~6.7% sequentially, but profitability remains weak with an operating loss of $8,019,000 (operating margin -226.7%) and GAAP net loss of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CV makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever